Generate Investment Management 13F: Exits NVO Stake

Generate Investment Management completely exited its position in Novo Nordisk A/S (NYSE: NVO), selling all 350000 shares it previously held. The complete close-out was disclosed in a regulatory filing with the SEC on October 14, 2026. Because 13F filings are backward-looking documents that reflect portfolio snapshots from the end of the reporting period, this exit may not represent the fund's current holdings today.

Other Institutional Activity in Novo Nordisk A/S

While Generate Investment Management walked away from the healthcare company, other large institutional players made notable moves with their own stakes. Dodge & Cox Inc. grew its holdings by 1063356 shares, ending with 20397110 shares worth about $792019818.0. LOOMIS SAYLES & CO L P lifted its position by 1577465 shares to hold 18594352 shares valued at roughly $722018722.0. On the other side, Franklin Resources, Inc. reduced its holdings by 3043140 shares, leaving it with 13041109 shares valued at $506386286.0. Price (T.Rowe) Associates Inc added 643748 shares to reach 11704719 shares worth $454494260.0, and Morgan Stanley boosted its stake by 790223 shares to finish with 11659869 shares valued at $452752734.0.

Novo Nordisk A Stock Up 1.7%

The stock recently traded around $38.76 as of October 16, 2026. That puts the shares down about 9.5% from their 50-day moving average and about 14.1% below their 200-day moving average. The shares are also positioned below their 52-week high of $64.16, though they sit roughly 10.4% above their 52-week low of $35.12.

Recent Earnings

Novo Nordisk generated trailing-twelve-month revenue of $329430990848.0 alongside basic earnings of $4.09 per share. Year-over-year revenue growth stood at 2.1%. The company sports a net profit margin of 35.3% and a return on equity of 59.8%. The company's next earnings report is scheduled for November 4, 2026.

Dividend

The company offers a dividend yield of 4.58%, backed by a dividend payout ratio of 43.1%.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the healthcare firm. On September 11, 2026, Morgan Stanley downgraded the stock with an Underweight rating and a $40.00 price target. Later, on October 12, 2026, BMO Capital maintained its Market Perform rating while lowering its price target to $40.00 from $47.00. The stock carries a consensus hold rating and an average price target of $45.85 across 12 analyst opinions.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based healthcare company focused on pharmaceutical products for diabetes, obesity, rare blood disorders, and hormone replacement therapies. Its therapies target widespread chronic conditions, making its market performance a key indicator for the broader pharmaceutical sector.

Bottom Line

Investors will look toward the upcoming earnings release on November 4, 2026, for fresh details on the company's financial health. Because 13F filings are historical records, market watchers should keep an eye on future SEC disclosures to see how institutional sentiment shifts under changing market conditions.